Question: is amrn a good buy?
Answer: Amarin is in a healthy financial position, with $624 million in cash and investments and assets that exceed its liabilities. ... With a price-to-book-value ratio of 5, Amarin is undervalued compared with its peers, including Acadia Pharmaceuticals (12.4) and Sarepta Therapeutics (9.6).